Latest / The Dales Report | Trade to Black
Gaetz's Appointment Looms: GOP Divided Over AG Role
Cybin (NYSE:CYBN) CEO Doug Drysdale will join us to discuss their latest trials, where they reported a 71% remission rate in patients with major depressive disorder (MDD) for their leading compound, CYB003. We’ll ask what’s next regarding their Phase III trial and the performance of the psychedelic stock. Plus, money is moving in the cannabis industry. Cory Azzalino, CEO of Eaze, will join us to highlight the company’s recent news about raising $10 million to acquire select assets of Eaze Technologies. Finally, Adam Goers, SVP of Corporate Affairs at The Cannabist Company Holdings (OTC…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.